ArticleFrontiers in genetics2025
Nonmetastatic cell 1 gene polymorphisms are associated with the clinical progression and prognoses of patients with colorectal cancer.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Genetic polymorphisms in the nonmetastatic cell 1 gene ( Methods: This study included 453 CRC patients and 464 controls. Genotyping of two polymorphisms (rs2302254 and rs16949649) in the promoter region of Results: The results revealed that the rs2302254 and rs16949649 polymorphisms were not associated with the risk of CRC. However, the rs2302254 TT mutant genotype was associated with an increased risk for advanced clinical stage and lymph node metastasis. Moreover, survival analysis revealed that patients with the homozygous mutant TT genotype of rs2302254 had significantly shorter disease-free survival (DFS) and overall survival (OS) times than patients with the homozygous wild-type CC genotype. Conclusion: The rs2302254 polymorphism might function as a potential molecular marker for predicting the progression and prognosis of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.